30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024 Download PDF Post navigationPreviousPrevious post:AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSNextNext post:The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceRelated PostsCorrective statement on the consolidated accounts as of December 31, 2023May 17, 2024Annual financial results as of 31 December, 2023May 15, 2024AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036May 13, 2024A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036May 13, 2024
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
